Antifungal activity of farnesol incorporated in liposomes and associated with fluconazole

Bezerra, Camila Fonseca; Júnior, José Geraldo de Alencar Santos; Honorato, Rosilaine de Lima; Santos, Antônia Thassya Lucas dos; Silva, Josefa Carolaine Pereira da; Silva, Taís Gusmão da; Leal, Antônio Linkoln Alves Borges; Rocha, Janaína Esmeraldo; Freitas, Thiago Sampaio de; Vieira, Thiago Adler Tavares; Bezerra, Maria Clara Fonseca; Sales, Débora Lima; Kerntopf, Marta Regina; Delmondes, Gyllyandeson de Araújo; Barbosa-Filho, José Maria; Peixoto, Laisla Rangel; Pinheiro, Allysson Pontes; Ribeiro-Filho, Jaime; Coutinho, Henrique Douglas Melo; Morais-Braga, Maria Flaviana Bezerra; Silva, Teresinha Gonçalves da

doi:10.1016/j.chemphyslip.2020.104987

Cited by 20 publications

(6 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The liposomes consist of amphiphilic phospholipids with hydrophilic head and hydrophobic tail, which aids in unique characteristics such as self-sealing of liposomes in aqueous media. In recent past, much research has been focused on the delivery of antibiotics [ 2 , 3 ], genes [ 4 , 5 ], antifungal [ 6 , 7 ], anti-inflammatory [ 8 , 9 ] and anti-cancer drugs [ 10 , 11 ] and also used in many pharmaceutical, biological and medical fields.…”

Section: Introductionmentioning

confidence: 99%

A Comprehensive Review on Novel Liposomal Methodologies, Commercial Formulations, Clinical Trials and Patents

Andra

Pammi²,

Bhatraju

et al. 2022

BioNanoSci.

View full text Add to dashboard Cite

Liposomes are well-recognized and essential nano-sized drug delivery systems. Liposomes are phospholipid vesicles comprised of cell membrane components and have been employed as artificial cell models to mimic structure and functions of cells and are of immense use in various biological analyses. Liposomes acquire great advantages and provide wide range of applications as useful drug carriers in pre-clinical and clinical trials. This review summarizes exclusively on scalable techniques for liposome preparation and focuses on the strengths and limitations with respect to industrial applicability. Also, this review discusses the updated recent advancements in biomedical applications with a mention of key highlights of commercially available formulations, clinical trials and patents in recent past. Furthermore, this review also provides brief information of the classification, composition and characterization of liposomes.

show abstract

Section: Introductionmentioning

confidence: 99%

A Comprehensive Review on Novel Liposomal Methodologies, Commercial Formulations, Clinical Trials and Patents

Andra

Pammi²,

Bhatraju

et al. 2022

BioNanoSci.

View full text Add to dashboard Cite

show abstract

“…Combining farnesol with traditional antifungal drugs such as amphotericin B, fluconazole, itraconazole, caspofungin, and natamycin has been shown to reduce minimum inhibitory concentrations (MIC) against resistant C. tropicalis cells [142,308,309]. In the case of fluconazole, it has been shown that the synergistic effect of farnesol is further enhanced when the quorum sensing molecule is previously incorporated into liposomes [310]. Similar effects were observed for exogenous tyrosol, which, when combined with traditional antifungal drugs such as amphotericin B, fluconazole, and itraconazole, significantly reduces biofilm formation and its metabolic activity; however, in the case of mature biofilms, similar effects were observed only for amphotericin B [144].…”

Section: Alternative Methods Formentioning

confidence: 99%

Similarities and Differences among Species Closely Related to Candida albicans: C. tropicalis, C. dubliniensis, and C. auris

Satała

Juszczak

Wronowska

et al. 2022

Cellular Microbiology

View full text Add to dashboard Cite

Although Candida species are widespread commensals of the microflora of healthy individuals, they are also among the most important human fungal pathogens that under certain conditions can cause diseases (candidiases) of varying severity ranging from mild superficial infections of the mucous membranes to life-threatening systemic infections. So far, the vast majority of research aimed at understanding the molecular basis of pathogenesis has been focused on the most common species—Candida albicans. Meanwhile, other closely related species belonging to the CTG clade, namely, Candida tropicalis and Candida dubliniensis, are becoming more important in clinical practice, as well as a relatively newly identified species, Candida auris. Despite the close relationship of these microorganisms, it seems that in the course of evolution, they have developed distinct biochemical, metabolic, and physiological adaptations, which they use to fit to commensal niches and achieve full virulence. Therefore, in this review, we describe the current knowledge on C. tropicalis, C. dubliniensis, and C. auris virulence factors, the formation of a mixed species biofilm and mutual communication, the environmental stress response and related changes in fungal cell metabolism, and the effect of pathogens on host defense response and susceptibility to antifungal agents used, highlighting differences with respect to C. albicans. Special attention is paid to common diagnostic problems resulting from similarities between these species and the emergence of drug resistance mechanisms. Understanding the different strategies to achieve virulence, used by important opportunistic pathogens of the genus Candida, is essential for proper diagnosis and treatment.

show abstract

“…Due to the benefits of using LPs as a drug delivery system, the incorporation of natural products may be a promising strategy in the fight against fungal infections (Salunkhe et al, 2021). Bezerra et al (2020) developed LPs by employing dipalmitoylphosphatidylcholine (DPPC, 5 mg), dipalmitoylphosphatidylserine (DPPS, 3 mg), CHOL (1 mg) as lipid fraction, and PBS (pH 7.2) as an aqueous portion, to promote the incorporation of farnesol, an important natural constituent present mainly in essential oils, and verify the effectiveness against Candida species. LP bases with and without farnesol were synthesized by the lipid‐film hydration technique and characterized using techniques such as vesicular size and morphology determination, polydispersity index, and average ZP.…”

Section: Future Nanotechnological Therapies For Fungal Infectionmentioning

confidence: 99%

“…fight against fungal infections(Salunkhe et al, 2021) Bezerra et al (2020). developed LPs by employing dipalmitoylphosphatidylcholine (DPPC, 5 mg), dipalmitoylphosphatidylserine (DPPS, 3 mg), CHOL (1 mg) as lipid fraction, and PBS (pH 7.2) as an aqueous portion, to promote the incorporation of farnesol, an important natural constituent present mainly in essential oils, and verify the effectiveness against Candida species.…”

mentioning

confidence: 99%

Natural product‐based nanomedicine applied to fungal infection treatment: A review of the last 4 years

Marena

Ramos

Carvalho

et al. 2022

Phytotherapy Research

View full text Add to dashboard Cite

Fungal infections are one of the main public health problems, especially in immunocompromised patients, nosocomial environments, patients with chronic diseases, and transplant recipients. These diseases are increasingly frequent and lethal because the microorganism has a high capacity to acquire resistance to available therapy. The main resistance factors are the emergence of new strains and the uncontrolled use of antifungals. It is, therefore, important to develop new methods that contribute to combating fungal diseases in the clinical area. Natural products have considerable potential for the development of new drugs with antifungal activity, mainly due to their biocompatibility and low toxic effect. This promising antimicrobial activity of natural products is mainly due to the presence of flavonoids, terpenes, and quinones, which explains their antifungal potential. Pharmaceutical nanotechnology has been explored to enhance the delivery, selectivity, and clinical efficacy of these products. Nanotechnological systems provide a safe and selective environment for various substances, such as natural products, improving antifungal activity. However, further safety experiments (in vivo or clinical trials) need to be carried out to prove the therapeutic action of natural products, since they may have undesirable, toxic, and mutagenic effects. Therefore, this review article addresses the main nanotechnological methods using natural products for effective future treatment against the main fungal diseases.

show abstract

Antifungal activity of farnesol incorporated in liposomes and associated with fluconazole

Cited by 20 publications

References 55 publications

A Comprehensive Review on Novel Liposomal Methodologies, Commercial Formulations, Clinical Trials and Patents

A Comprehensive Review on Novel Liposomal Methodologies, Commercial Formulations, Clinical Trials and Patents

Similarities and Differences among Species Closely Related to Candida albicans: C. tropicalis, C. dubliniensis, and C. auris

Natural product‐based nanomedicine applied to fungal infection treatment: A review of the last 4 years

Contact Info

Product

Resources

About